Carimune Market Report 2026

Carimune Market Overview

• The Carimune market growth in the historic period has been driven by prevalence of primary immunodeficiency, reliance on plasma derived therapies • Market expansion is supported by growth in igiv demand, increasing autoimmune diagnoses • Growth Driver: Impact Of Rising Immunological Disorders On Carimune Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Carimune Market?

Carimune is a brand name for immune globulin intravenous (IGIV), a medication made from pooled human plasma. It is used to treat various conditions related to immune deficiencies and autoimmune disorders. Carimune provides antibodies to help boost the immune system of individuals with weakened immune responses. The product helps by replacing antibodies that are missing or deficient in the patient's body, which assists in fighting infections and reducing the activity of abnormal immune responses. The main types of carimune formulation include liquid formulation, lyophilized powder formulation, and concentrated formulation. Liquid formulation is a pre-prepared, ready-to-use version of carimune that does not require reconstitution before administration. It is used for immunodeficiency disorders and autoimmune disorders and is used by various end users, including hospitals and clinics, home care settings, specialized healthcare providers, retail pharmacies, and physician offices.

What Is The Carimune Market Growth Forecast?

The growth in the forecast period can be attributed to growth in igiv demand, increasing autoimmune diagnoses, expansion of home infusion care, improved plasma collection capacity, rising healthcare spending. Major trends in the forecast period include rising demand for intravenous immunoglobulin, expansion of autoimmune disorder management, growing use in immunodeficiency treatment, increase in long term immune modulation therapy, strengthening of specialty infusion services.

Global Carimune Market Segmentation

1) By Formulation: Liquid Formulation, Lyophilized Powder Formulation, Concentrated Formulation 2) By Indication: Immunodeficiency Disorders, Autoimmune Disorders 3) By End User: Hospitals And Clinics, Home Care Settings, Specialized Healthcare Providers, Retail Pharmacies, Physician Offices

What Are The Drivers Of The Carimune Market?

The high prevalence of immunological disorders is expected to drive the growth of the carimune market going forward. Immunological disorders are conditions caused by dysfunctions in the immune system, leading to abnormal immune responses such as autoimmune diseases, immunodeficiencies, and hypersensitivities. The increasing prevalence of immunological disorders is largely due to factors such as better diagnosis, environmental changes, genetic predisposition, and lifestyle factors. Carimune is essential for immunological disorders as it provides immune support by delivering antibodies to patients with immune deficiencies or autoimmune conditions. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the high prevalence of immunological disorders is driving the growth of the carimune industry. The rising healthcare expenditure is expected to propel the growth of the carimune market going forward. Healthcare spending refers to the total financial resources allocated by individuals, governments, private insurers, and other entities towards the provision of healthcare services and products. The rise in healthcare spending is attributed to an aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare expenditure supports carimune by enabling increased investment in advanced immunoglobulin therapies, improving access to high-quality treatments for immune disorders, and strengthening healthcare infrastructure to ensure efficient diagnosis and administration. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in the UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rising healthcare expenditure is driving the growth of the carimune industry. The growing geriatric population is expected to drive the growth of the carimune market going forward. The geriatric population refers to individuals aged 65 and older, typically associated with the later stages of life. The geriatric population is growing due to increased life expectancy and advancements in healthcare. Carimune is essential for the growing geriatric population as it helps manage immune deficiencies and supports overall immune health in aging individuals. For instance, in October 2025, according to the World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, by 2030, one in six people globally will be aged 60 or older, with the population of individuals in this age group projected to double to 2.1 billion by 2050. Therefore, the growing geriatric population is driving the growth of the carimune industry.

Key Players In The Global Carimune Market

Major companies operating in the carimune market are CSL Behring AG

Regional Insights

North America was the largest region in the carimune market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Carimune Market?

The carimune market consists of sales of albumin, hyperimmune globulin, vaccines and blood plasma derivatives. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Carimune Market Report 2026?

The carimune market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the carimune industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.